Biotech · Private company
Ascendis Pharma A/S
Track this companyFree. Adds Ascendis Pharma A/S to your Dealase workspace and tells you when its record changes.
Clinical trials94 recruiting or active
Pipeline programs10From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline10
- Lonapegsomatropin [SKYTROFA®]Phase 3 · Turner SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- Somatropin Pen InjectorPhase 3 · Turner SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- TransCon hGHPhase 3 · Growth Hormone Deficiency, PediatricClinicalTrials.gov · fetched Nov 12, 2026
- NavepegritidePhase 2 · AchondroplasiaClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 2 · Head and Neck NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- TransCon CNPPhase 2 · AchondroplasiaClinicalTrials.gov · fetched Nov 12, 2026
- TransCon IL-2 β/γPhase 2 · Head and Neck NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- TransCon PTHPhase 2 · HypoparathyroidismClinicalTrials.gov · fetched Nov 12, 2026
- TransCon TLR7/8 AgonistPhase 2 · Head and Neck NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- PalopegteriparatideHypoparathyroidismClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials9
- A Study to Assess the Amount of Palopegteriparatide in Breast Milk of Lactating Females Requiring YORVIPATH® (Palopegteriparatide)RECRUITING · started Mar 19, 2026ClinicalTrials.gov NCT07264634 · fetched Nov 12, 2026
- A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and BreastfeedingRECRUITING · started Feb 18, 2026ClinicalTrials.gov NCT07345494 · fetched Nov 12, 2026
- Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient DisordersPHASE3 · RECRUITING · started Dec 12, 2025ClinicalTrials.gov NCT07221851 · fetched Nov 12, 2026
- A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With AchondroplasiaPHASE2 · RECRUITING · started Jan 23, 2024ClinicalTrials.gov NCT06079398 · fetched Nov 12, 2026
- TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell CarcinomaPHASE2 · TERMINATED · started Sep 29, 2023ClinicalTrials.gov NCT05980598 · fetched Nov 12, 2026
- A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of TransCon CNP Administered Once Weekly in Prepubertal Children With AchondroplasiaPHASE2 · COMPLETED · started Jun 24, 2020ClinicalTrials.gov NCT04085523 · fetched Nov 12, 2026
- A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With HypoparathyroidismPHASE2 · COMPLETED · started Aug 27, 2019ClinicalTrials.gov NCT04009291 · fetched Nov 12, 2026
- A Multi-center, Longitudinal, Observational Study of Children With AchondroplasiaCOMPLETED · started Jun 19, 2019ClinicalTrials.gov NCT03875534 · fetched Nov 12, 2026
- A Long-Term Trial Investigating Safety and Efficacy of TransCon hGH in Children With Growth Hormone Deficiency Who Have Completed a Prior TransCon hGH Clinical TrialPHASE3 · COMPLETED · started Dec 19, 2017ClinicalTrials.gov NCT03344458 · fetched Nov 12, 2026